Skip to main content
. 2021 Jan 28;15(8):1362–1375. doi: 10.1093/ecco-jcc/jjab001

Table 1.

Patient characteristics

Normal, N = 11 UC*, N = 20 CD*, N = 22
Age, years
 18–40 2 [18%] 9 [45%] 10 [45%]
 ≥ 40 9 [82%] 11 [55%] 12 [55%]
Sex
 Male 5 [45%] 11 [55%] 12 [55%]
 Female 6 [55%] 9 [45 %] 10 [45%]
Smoking status
 Never smoked 4 [36%] 10 [52%] 10 [45%]
 Ex smoker 4 [36%] 7 [35%] 7 [32%]
 Current smoker 3 [28%] 3 [13%] 5 [23%]
Location
 Caecum 9 [48%]
 Right colon 2 [18%] 1 [4 %]
 Transverse colon 3 [27%] 2 [10%] 1 [4 %]
 Left colon 2 [18%] 5 [25%] 2 [8 %]
 Sigmoid/rectum 4 [37%] 13 [65%] 4 [16%]
 Colon, mixed 5 [20%]
Therapy
 5-ASA n/a 3 [15%] 0
 Corticosteroids n/a 2 [10%] 0
 5-ASA/corticosteroids n/a 0 [0%] 6 [27 %]
 Biologics n/a 0 [0%] 7 [32 %]
 Mix of biologics n/a 5 [23%]
 Corticosteroids/immunomodulators 10 [50%] 0
 No treatment 11 [100%] 5 [25%] 4 [18%]

*All patients included in this study had active inflammatory disease with mucosal inflammation scored as moderate/severe.